Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS M SANDER

Allopathic & Osteopathic Physicians Dermatology

NPI
1285635813
CMS profile
58428
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,979.73

313 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 313 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS M SANDER

NPI 1285635813 · CMS profile ID 58428

Allopathic & Osteopathic Physicians / Dermatology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 313 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285635813?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS M SANDER, NPI 1285635813, CMS profile ID 58428. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 313 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285635813?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HANS M SANDER, NPI 1285635813, CMS profile ID 58428. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 313 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285635813?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HANS M SANDER, NPI 1285635813, CMS profile ID 58428, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 313 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1285635813?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

313 matching records · $6,979.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 313 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 313.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $21.2208/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993348449 CMS
GENZYME CORPORATION $12.2308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049737051 CMS
UCB, Inc. $25.3808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021436853 CMS
AbbVie Inc. $50.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810671 CMS
Janssen Biotech, Inc. $9.1508/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370075 CMS
PFIZER INC. $19.0608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050676947 CMS
Janssen Biotech, Inc. $23.3608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370167 CMS
Janssen Biotech, Inc. $12.5108/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370011 CMS
Regeneron Healthcare Solutions, Inc. $15.1708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999410873 CMS
PFIZER INC. $2.3608/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049505119 CMS
Sun Pharmaceutical Industries Inc. $15.6408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053855707 CMS
Janssen Biotech, Inc. $25.7908/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370115 CMS
E.R. Squibb & Sons, L.L.C. $9.1708/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015806679 CMS
Incyte Corporation $21.9308/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044853445 CMS
Dermavant Sciences, Inc. $10.8808/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991246377 CMS
AbbVie Inc. $11.7208/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810667 CMS
GENZYME CORPORATION $24.8708/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049736989 CMS
Janssen Biotech, Inc. $26.0508/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080723813 CMS
Arcutis Biotherapeutics, Inc. $13.9908/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720755 CMS
Janssen Biotech, Inc. $16.6808/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370187 CMS
Novartis Pharmaceuticals Corporation $6.6108/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993348447 CMS
AbbVie Inc. $124.2808/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810661 CMS
Arcutis Biotherapeutics, Inc. $10.9408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720737 CMS
AbbVie Inc. $26.7908/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810655 CMS
Janssen Biotech, Inc. $28.0507/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370095 CMS
AbbVie Inc. $8.3107/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810649 CMS
Sun Pharmaceutical Industries Inc. $19.3707/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053855715 CMS
Janssen Biotech, Inc. $133.6107/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988369995 CMS
Janssen Biotech, Inc. $13.0507/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370105 CMS
UCB, Inc. $25.4407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021436859 CMS
Dermavant Sciences, Inc. $25.3707/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991246373 CMS
GENZYME CORPORATION $10.7007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049737001 CMS
Janssen Biotech, Inc. $13.0807/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370085 CMS
AbbVie Inc. $10.6207/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810644 CMS
E.R. Squibb & Sons, L.L.C. $17.3007/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015806643 CMS
E.R. Squibb & Sons, L.L.C. $26.4907/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015806647 CMS
Incyte Corporation $23.7607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044853291 CMS
AbbVie Inc. $8.4507/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810627 CMS
AbbVie Inc. $8.4507/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810633 CMS
AbbVie Inc. $15.5007/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810639 CMS
Dermavant Sciences, Inc. $17.3607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991246369 CMS
Regeneron Healthcare Solutions, Inc. $30.3307/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999410867 CMS
Janssen Biotech, Inc. $11.7907/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988370257 CMS
Amgen Inc. $32.3807/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020585971 CMS
GENZYME CORPORATION $21.1807/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049736995 CMS
PFIZER INC. $20.2107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049524349 CMS
Novartis Pharmaceuticals Corporation $18.6507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993348443 CMS
AbbVie Inc. $12.9807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998810621 CMS
Arcutis Biotherapeutics, Inc. $14.8007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044720767 CMS
PFIZER INC. $14.4607/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050521339 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,587.52 182
PY2020 $1,924.61 100
PY2021 $3,175.80 170
PY2022 $5,908.89 255
PY2023 $6,979.73 313
PY2024 $6,106.60 299
PY2025 $5,842.32 286

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $72,131.50 28
PY2024 Principal investigator $22,145.50 3
PY2023 Principal investigator $14,959.84 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,436.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610534
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610552
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610556
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610559
Principal investigator 1 Incyte Corporation $1,717.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610570
Principal investigator 1 Incyte Corporation $1,684.00 12/19/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610594
Principal investigator 1 SANOFI US SERVICES INC. $6,000.00 12/12/2025 Non-covered Recipient Entity
Oliver Street 501(a) Inc
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226100440
Principal investigator 1 Incyte Corporation $2,218.70 12/05/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610578
Principal investigator 1 Incyte Corporation $79.00 11/21/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610538
Principal investigator 1 Incyte Corporation $1,873.00 11/21/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610544
Principal investigator 1 Incyte Corporation $1,097.20 11/21/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610548
Principal investigator 1 Incyte Corporation $2,563.00 11/21/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610583
Principal investigator 1 Incyte Corporation $47.00 11/21/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610586
Principal investigator 1 Incyte Corporation $47.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610526
Principal investigator 1 Incyte Corporation $47.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610530
Principal investigator 1 Incyte Corporation $1,873.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610563
Principal investigator 1 Incyte Corporation $1,796.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610567
Principal investigator 1 Incyte Corporation $656.60 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610574
Principal investigator 1 Incyte Corporation $79.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610591
Principal investigator 1 Incyte Corporation $2,563.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610603
Principal investigator 1 Incyte Corporation $2,563.00 10/22/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610607
Principal investigator 1 Incyte Corporation $9,000.00 10/02/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610521
Principal investigator 1 Incyte Corporation $3,000.00 10/02/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610599
Principal investigator 1 Incyte Corporation $79.00 09/25/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610510
Principal investigator 1 Incyte Corporation $2,042.50 09/25/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610514
Principal investigator 1 Incyte Corporation $2,563.00 09/25/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS OF CEDAR PARK MEDICAL CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610518
Principal investigator 1 Amgen Inc. $18,401.00 04/24/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648523
Principal investigator 1 Amgen Inc. $8,565.50 01/27/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS JOLLYVILLE
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246650978